Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research reports (Loss) of ₹2,458 lakhs in Q2 FY27
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 02 Nov 2026, 08:05 PM IST · BSE ID: 86cd4d0f-f4e3-42b4-83be-42c6e3d8114f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported a standalone loss of ₹2,458 lakhs this quarter, while revenue from operations increased.
🤖 AI Summary
- Standalone loss for Q2 FY27 was ₹2,458 lakhs, compared to a loss of ₹7,597 lakhs in Q2 FY26.
- Total revenue from operations reached ₹3,003 lakhs in Q2 FY27, up from ₹786 lakhs in Q2 FY26.
- Half-year loss stood at ₹4,556 lakhs for H1 FY27, versus a loss of ₹12,800 lakhs in H1 FY26.
- Half-year revenue from operations was ₹6,995 lakhs in H1 FY27, compared to ₹1,750 lakhs in H1 FY26.
- Basic and diluted loss per equity share was ₹0.76 for Q2 FY27, against ₹2.34 in Q2 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
3,003 lakhs
Profit / (loss) for the period (Q2 FY27)
(2,458) lakhs
Total comprehensive profit / (loss) for the period (Q2 FY27)
(2,622) lakhs
Basic and diluted earnings / (loss) per equity share (Q2 FY27)
(0.76)
Revenue from operations (H1 FY27)
6,995 lakhs
Profit / (loss) for the period (H1 FY27)
(4,556) lakhs
🏢 How This Affects the Company
Revenue from operations for Q2 FY27 increased significantly to ₹3,003 lakhs from ₹786 lakhs in the prior year comparable quarter. This growth was primarily from contracts with customers, following a licensing agreement termination in Q1 FY27 which resulted in a revenue recognition of ₹2,921 lakhs.
The company reported a reduced standalone loss of ₹2,458 lakhs in Q2 FY27, compared to ₹7,597 lakhs in Q2 FY26. Total expenses for Q2 FY27 were ₹7,823 lakhs, lower than ₹8,384 lakhs in the prior year comparable quarter, contributing to the improved loss figures.
The Company reported 'Pharmaceutical Research and Development' as its sole reportable business segment, indicating continued focus on R&D activities. Employee benefits expense decreased to ₹2,389 lakhs in Q2 FY27 from ₹2,619 lakhs in Q2 FY26.
The ongoing losses, though reduced, indicate a continued cash outflow from operations. However, the company's equity base increased to ₹1,43,638 lakhs as of September 30, 2026, from ₹1,33,358 lakhs as of March 31, 2026, partly due to warrant allotment which could provide future capital.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's ongoing financial performance, specifically the reported standalone loss of ₹2,458 lakhs for Q2 FY27.
🔍
Management Signal
The financial results indicate management's continued focus on R&D activities while managing expenses, leading to a reduced loss for the quarter.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — monitor changes in revenue from operations and expenses.
Updates on pharmaceutical research and development pipeline progress.
Announcements regarding warrant exercise by Shanghvi Finance Private Limited and related capital infusion.
MEDIUM RISK
The company continues to report losses, although reduced, indicating ongoing operational costs without consistent profitability.
💡 Investor Takeaway
Sun Pharma Advanced Research Company reported a Q2 FY27 standalone loss of ₹2,458 lakhs, an improvement from ₹7,597 lakhs loss in Q2 FY26. Revenue from operations increased to ₹3,003 lakhs in Q2 FY27 from ₹786 lakhs in Q2 FY26, primarily driven by contract revenue.
⚖️ Strengths & Concerns
✅ Positives
- Revenue from operations increased to ₹3,003 lakhs in Q2 FY27, up from ₹786 lakhs in Q2 FY26, representing strong year-on-year growth.
- Loss for the period reduced to ₹2,458 lakhs in Q2 FY27, a significant improvement from the ₹7,597 lakhs loss in Q2 FY26.
⚠️ Concerns
- The company continues to report a standalone loss for the quarter and half-year, with a loss of ₹2,458 lakhs in Q2 FY27.
- Total expenses remain substantial at ₹7,823 lakhs for Q2 FY27, exceeding total income of ₹5,365 lakhs for the same period.
📅 Company Track Record
The previous year's financials (FY26) included significant 'Other operating revenue' of ₹1,84,002 lakhs from the sale of a Priority Review Voucher (PRV) for Sezaby® in April 2026. This item is not recurring in H1 FY27. For the quarter ended June 30, 2026, the company recognised revenue of ₹2,921 lakhs related to a non-refundable consideration from a terminated licensing agreement.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Sun Pharma Advanced Research Company's standalone loss in Q2 FY27?
Sun Pharma Advanced Research Company reported a standalone loss of ₹2,458 lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was the total revenue from operations for Sun Pharma Advanced Research Company in Q2 FY27?
The total revenue from operations for Sun Pharma Advanced Research Company in Q2 FY27 was ₹3,003 lakhs.
How did the loss per share change for Sun Pharma Advanced Research Company in Q2 FY27?
The basic and diluted loss per equity share for Q2 FY27 was ₹0.76, compared to a loss of ₹2.34 in Q2 FY26.
What was Sun Pharma Advanced Research Company's loss for the half-year ended September 30, 2026?
For the half-year ended September 30, 2026 (H1 FY27), Sun Pharma Advanced Research Company reported a standalone loss of ₹4,556 lakhs.
What was the total equity of Sun Pharma Advanced Research Company as of September 30, 2026?
The total equity of Sun Pharma Advanced Research Company as of September 30, 2026, was ₹1,43,638 lakhs.
Questions based on this BSE filing only. For information purposes.